Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab…
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)2.8 million injections of repackaged off-label bevacizumab in Europe each year 1 ISELIN, N.J., June02, 2025(GLOBE NEWSWIRE) --Outlook Therapeutics, Inc.(Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that...
Nasdaq GlobeNewswire
02/06/2025
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific…
"Alkermes is honored to present at these notable scientific meetings, sharing our research and insights with thought leaders and healthcare providers from across the field of psychiatry," said Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President, Research & Development at Alkermes. "Alkermes is committed to contributing to the advancement of patient care and the body of evidence in neuro-psychiatry, including for the treatment of schizophrenia and bipolar…
PR Newswire
02/06/2025
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to…
BNT327, BioNTech's PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor typesThe co-development and co-commercialization collaboration with a 50/50 profit/loss split will leverage both partners' expertise, resources and global footprint to accelerate BNT327's path towards potential regulatory approvals and market launches...
Nasdaq GlobeNewswire
02/06/2025
Transactions under Novonesis' share buyback program
Please read the announcement in PDF Attachment 2025_27_Share_buyback_program
Nasdaq GlobeNewswire
02/06/2025
BioArctic's Capital Markets Day 2025 - entering a new era of growth
At the Capital Markets Day, management will outline BioArctic's ambitions for 2030 which focuses on building Sweden's next major pharmaceutical company. This will be achieved by: At the Capital Markets Day, management will outline BioArctic's ambitions for 2030 which focuses on buildingSweden'snext major pharmaceutical company. This will be achieved by: To achieve this, the company will accelerate innovation into a broader area of severe brain diseases, proactively work with business...
PR Newswire
02/06/2025
iOnctura bolsters leadership team with new appointments
Steven Sciuto is a seasoned finance executive with more than 15 years of corporate finance leadership and capital markets experience within the life sciences industry. He has played pivotal roles in scaling financial operations, raising over $400 million through private and public financings, and leading complex transactions. Prior to joining iOnctura, Steven was most recently at Neurogene Inc., where he held various roles of increasing responsibility within the finance organization, culminating…
PR Newswire
02/06/2025
BIAL Announces Oral Presentation at GBA1 Meeting 2025
Raquel Costa, the study lead, comments, 'We're witnessing a growing enthusiasm around the potential of BIA 28-6156 across the Parkinson's community and are eager to present further insights into the ACTIVATE study design at the upcoming GBA1 Meeting. We believe this investigational therapy could represent a significant step forward with the potential to be a much-needed disease-modifying treatment option for patients living with GBA-PD.' Raquel Costa, the study lead, comments, ' We're...
PR Newswire
02/06/2025
ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to…
Paul Mann, CEO of ASP Isotopes, emphasized the agreement's significance: "By supplying Gd-160, we are eliminating a major bottleneck in the development of Tb-161 therapies. Our investment in enrichment technology positions us to support the radiopharmaceutical industry's growing demand for stable isotopes. This partnership accelerates the path to clinical adoption of Tb-161, which could redefine cancer treatment paradigms." Paul Mann, CEO of ASP Isotopes, emphasized the agreement's...
PR Newswire
02/06/2025
Expanding a Stroke Legacy: Terumo Neuro Announces EMEA Commercial Availability…
Leveraging more than ten years of neurovascular catheter innovation, physician partnerships and proven clinical performance1-9, the SOFIA™ 88 Neurovascular Aspiration Catheter offers an 0.088-inch inner diameter with proprietary engineering enhancements designed to provide the following benefits: Leveraging more than ten years of neurovascular catheter innovation, physician partnerships and proven clinical performance 1-9, the SOFIA™ 88 Neurovascular Aspiration Catheter offers an 0.088-inch...
PR Newswire
02/06/2025
Clarivate and CAPES Expand Landmark Partnership to Power Research and Innovation…
As a key agency under Brazil's Ministry of Education, CAPES plays a vital role in advancing postgraduate education, supporting high-level training, and fostering international scientific collaboration. A long-standing partner to CAPES, Clarivate began its collaboration with the agency in 2001, when the Web of Science became one of the first databases integrated into the CAPES Portal. This new agreement builds on that legacy, delivering enhanced access to solutions including Web of Science…
PR Newswire
02/06/2025
Novartis Pluvicto™ demonstrates statistically significant and clinically…
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at...
Nasdaq GlobeNewswire
02/06/2025
Ipsen S.A. - Initiation of the share buy-back program
Regulated information Ipsen initiates a share buy-back program to cover its free employee share-allocation planPARIS, FRANCE, 2 June 2025 -Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it has appointed an investment-services provider to purchase an aggregate number of Ipsen S.A. shares up to 600,000, or about 0.72% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen's free...
Nasdaq GlobeNewswire
02/06/2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in…
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunologyAdds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio Paris and Cambridge, MA. June 2, 2025. Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other...
Nasdaq GlobeNewswire
02/06/2025
Sandoz launches first and only interchangeable denosumab biosimilars in US…
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEWYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in USImproves access for patients living with osteoporosis and cancer-related skeletal events in US and enhances US biosimilar portfolioBuilds on established experience and leadership in oncology and immunology biosimilarsBasel, June 2, 2025 –Sandoz...
Nasdaq GlobeNewswire
02/06/2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in…
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunologyAdds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio Paris and Cambridge, MA. June 2, 2025. Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other...
Nasdaq GlobeNewswire
02/06/2025
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation…
JIN-A02 is an oral, fourth-generation EGFR-TKI designed to overcome resistance mutations (such as C797S) that develop after treatment failure with third-generation EGFR-TKIs, which are currently the first-line therapy for EGFR-mutant Non-small cell lung cancer (NSCLC). It is currently undergoing clinical trials in South Korea, the United States, Thailand, and other countries. Key efficacy and safety results from Part A (dose escalation) of the multi-center clinical trial (NCT05394831) were…
PR Newswire
02/06/2025
SIBIONICS Hosts the 3rd AGP&DTx Summit Forum: Breakthroughs Ahead
The main forum focused on the theme "Milestones & Future Strategies of the Project on Standardizing Nursing Practices in AGP Reporting," offering deep insights into the current landscape and future of digital diabetes management. The main forum focused on the theme "Milestones & Future Strategies of the Project on Standardizing Nursing Practices in AGP Reporting," offering deep insights into the current landscape and future of digital diabetes management. A key…
PR Newswire
01/06/2025
Novartis Kisqali® reduces risk of recurrence in younger patients with early…
33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year post-treatment analysis 1 Tolerability remained consistent, with fewer treatment discontinuations due to adverse events among pre-menopausal patients 1 Rising breast cancer diagnosis rates and more aggressive disease in younger women underscore importance of early detection and care with effective and tolerable treatments that help...
Nasdaq GlobeNewswire
01/06/2025
"TNFS": A Saudi-Led Initiative Sets Regional Benchmark in Tobacco Harm Reduction
Over the past year, tangible results have begun to emerge in the Kingdom: Over the past year, tangible results have begun to emerge in the Kingdom: OnMay 29, the TNFS initiative hosted the "TNFS 2025 Summit" inRiyadh, bringing together more than 100 experts from 15 countries. The summit focused on regional challenges and scientific solutions for reducing tobacco-related harm, concluding with several key recommendations, including: Looking ahead, TNFS will begin translating the...
PR Newswire
31/05/2025
New data show Roche's Itovebi significantly extended survival in a certain type…
The Itovebi TM(inavolisib)-based regimen reduced the risk of death by more than 30% in people withPIK3CA -mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and fulvestrant alone 1 ThePIK3CAmutation is found in approximately 40% of HR-positive advanced breast cancers and is associated with a poor prognosis 2,3 New data are being presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published...
Nasdaq GlobeNewswire
31/05/2025
Late-breaking analysis demonstrates characteristics associated with long-term…
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma 1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated with long-term survival, with median overall survival of 19.5 months amongst long-term survivors receiving Onivyde ®plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) regimen as a first-line therapy 2 Dose reductions and/or treatment delays for...
Nasdaq GlobeNewswire
31/05/2025
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting…
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to >2.5 years IMA203 PRAME cell therapy one-time infusion in all melanoma patients shows cORR of 56%; mDOR of 12.1 months at mFU of 13.4 months; mPFS of 6.1 months; mOS of 15.9 months Cutaneous melanoma subgroup post-checkpoint inhibitor shows...
Nasdaq GlobeNewswire
31/05/2025
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in…
More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of care treatment, and one-quarter are left untreatedLTC residents are often given a broader diagnosis of extrapyramidal syndrome, which can lead to incorrect treatment options for TD Teva is committed to continuing to advance research to better understand and help address unmet needs among patients living with TD in LTC settings as well as other settings...
Nasdaq GlobeNewswire
31/05/2025
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes…
Real-world claims studies evaluating UZEDY ®(risperidone) also showimproved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options Latest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-'749 after more than 3,400 subcutaneous injections in study participants to dateAs a leader in neuroscience, Teva is committed to researching and developing long-acting treatment...
Nasdaq GlobeNewswire
31/05/2025
Altri Comunicati
